What The Gene Therapy Sector Doesn't Understand About CRISPR
By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
I sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.
What You’re Probably Thinking
It’s smart to temper the hype of the actual data. Like any medicine or tool, you must figure out the biology and determine if CRISPR-edited stem cells or other cell types are the right tool.
The Truth of the Matter
CRISPR-edited stem cells can be applied across a broad category of diseases. There will be more limited application depending on the disease itself.
This website uses cookies to ensure you get the best experience on our website. Learn more